July 30, 2010 - Geron Corporation (Nasdaq: GERN) announced that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron's Investigational New Drug (IND) application has been lifted and the company's Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury may proceed...[...]
...Additionally, we are now formally exploring the utility of GRNOPC1 in other degenerative CNS disorders including Alzheimer's, multiple sclerosis and Canavan disease."...
[...]
Other Potential Neurological Indications for GRNOPC1
[...]
Alzheimer's Disease: Alzheimer's disease is a progressive, fatal, degenerative disorder that attacks the neurons in the brain, resulting in loss of memory, cognitive function such as reasoning and language, and behavioral changes. According to the Alzheimer's Association an estimated five million people in the United States have Alzheimer's disease. GRNOPC1 is being evaluated in animal models of Alzheimer's disease in collaboration with Professor Frank M. LaFerla, Director of the Institute for Memory Impairments and Neurological Disorders (UCI MIND) at the University of California, Irvine...Geron's Press Release -
